Top 5 bladder cancer articles of 2019

Roger Li, MD, Moffit Cancer Center, was awarded the grant to study the novel oncolytic virus drug CG0070 in patients with intermediate-risk non–muscle-invasive bladder cancer.

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

“There is an urgent need for new treatment options for [patients with] urothelial carcinoma, many of whom find themselves out of options after progressing on immune checkpoint inhibitors," said Sergio Santillana, MD.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

At 6 months, high-grade RFS in the BCG group was 76%, compared with 92% in the gemcitabine and docetaxel group.

In an episode of Cleveland Clinic’s Cancer Advances podcast, Christopher Weight, MD, center director of Urologic Oncology at Cleveland Clinic, discusses robot-assisted retroperitoneal lymph node dissection.